Register for this two-day intensive, clinically driven virtual educational event designed to enhance your expertise in psychopharmacology while learning in an interactive setting from international experts and leaders in the field. This virtual masterclass will explore psychopharmacological advances and emerging treatments, current evidence-based approaches along with nuanced clinical strategies to enhance your medical decision making. This online event will showcase expert speakers through live webinars and engaging Q&A discussions.
The content is designed for clinicians who manage mental health issues and psychiatric disorders and are looking to deepen their understanding of psychopharmacological advances across the diagnostic spectrum, especially based on cutting-edge research and real-world clinical experience.
Format
Recorded webinar content, originally recorded on October 3-4, 2025.
Learning Objectives:
By participating in this course, learners will be equipped with clinical information to:
- Evaluate and apply recent advances in psychopharmacology to improve treatment outcomes for a variety of psychiatric disorders.
- Identify best practices for managing adverse effects, drug-drug interactions, and polypharmacy, across the diagnostic spectrum.
- Apply critical thinking to real-world case scenarios involving complex psychopharmacological decisions.
- Engage in meaningful dialogue with faculty experts by posing questions to confirm nuanced treatment decisions and gain deeper clinical insight.
References
- Telles-Correia D. New Advances in Psychopharmacology: From Basic Science to Clinical Research. Curr Top Med Chem. 2022;22(15):1235. doi: 10.2174/156802662215220706154308. PMID: 35974669.
- Glick ID, Balon R, DeBattista C. Raising the Quality of Psychopharmacology Clinical Psychiatric Practice: Elements of Good Psychopharmacology Care. J Clin Psychopharmacol. 2022 Jan-Feb 01;42(1):3-6. doi: 10.1097/JCP.0000000000001499. PMID: 34928556.
- Rothschild AJ. Psychopharmacology: Back to Basics. J Clin Psychopharmacol. 2022 Jan-Feb 01;42(1):1-2. doi: 10.1097/JCP.0000000000001518. PMID: 34928555.
Target Audience
Psychiatrists, Non-psychiatrist Physicians, Resident/Fellows, Medical Students, Pharmacists, Nurses, Psychologists, and other mental health professionals.
Instructional Level
Introductory, Intermediate
Estimate Time to Complete
Estimated Duration: 16.5 hours
Program Start Date: October 16, 2025
Program End Date: October 16, 2028
Schedule:
All times listed are in Eastern Daylight Time (EDT).
| Session Title |
Presenter Name |
| Opening Remarks |
Dr. Marketa Wills |
| Session 1 - Schizophrenia |
Dr. Nina Kraguljac |
| Session 2 - Anxiety Disorders |
Dr. Charles Nemeroff |
| Moderated Discussion |
|
| Session 3 - Depressive Disorders |
Dr. Alan Schatzberg |
| Session 4 - TMS |
Dr. Heather Ward |
| Session 5 - Ketamine |
Dr. John Krystal |
| Session 6 - Bipolar Disorder |
Dr. Mark Frye |
| Moderated Discussion |
|
| Session 7 - ADHD |
Dr. Timothy Wilens |
| Moderated Discussion |
|
| Session 8 - Drug Interactions |
Dr. Jonathan Alpert |
| Moderated Discussion |
|
| Session 9 - Eating Disorders |
Dr. Erikka Taylor |
| Session 10 - Anti-Obesity Medications |
Dr. Kimberly Gudzune |
| Moderated Discussion |
|
| Session 11 - Substance Use Disorders |
Dr. Ihsan Salloum |
| Session 12 - Psychedelics |
Dr. Roger McIntyre |
| Moderated Discussion |
|
| Session 13 - Pediatric Psychopharmacology |
Dr. Manpreet Singh |
| Session 14 - Geriatric Psychopharmacology |
Dr. Rajesh Tampi |
| Moderated Discussion |
|
How to Earn Credit
Participants who wish to earn AMA PRA Category 1 Credit™ or a certificate of participation may do so by viewing the live presentation and completing the evaluation. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (other disciplines) showing the event date and hours earned.
Continuing Education Credit
In support of improving patient care, the American Psychiatric Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The APA designates this live event for a maximum of 16.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Planner Disclosures
The American Psychiatric Association adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME activity — including faculty, planners, reviewers or others — are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty
- Alan Schatzberg, MD. Dr. Schatzberg has ownership Interest (includes stock, stock options, patent, or other intellectual property) in Alto Neuroscience, ANeuroTech, and NeuraWell.
- Charles Nemeroff, MD, PhD. Reports financial relationships with Janssen Research & Development LLC, BioXcel Therapeutics, Silo Pharma, EcoR1 Capital LLC, EmbarkNeuro, ITI Inc, LUCY Scientific Discovery, Relmada Therapeutics, Heading Health, SynapseBio, Ninnion, Pasithea, Skyland Trails, ANeuroTech, Abbott Laboratories, Engrail Therapeutics, Clexio Bioscience LTD, Galen Mental Health LLC, Goodcap Pharmaceuticals Inc, Sage Therapeutics Inc, Senseye Inc, Precisement Health, Autobahn Therapeutics, Inc, EMA Wellness, Denovo Biopharma LLC, Acadia, Alvogen, Reunion Neuroscience, Neurocrine Biosciences LLC, Kivira Health Inc, Wave Neuroscience, Patient Square Capital LP, Invisalert Solutions Inc.
- Erikka Taylor, MD, MPH.
- Heather Ward, MD.
- Ihsan Salloum, MD, MPH.
- John Krystal, MD, LFAPA.
- Jonathan Alpert, MD, PhD, DLFAPA.
- Kimberly Gudzune, MD, MPH. Reports financial relationships with Novo Norodisk and Eli Lilly & Company.
- Manpreet Singh, MD, MS. Reports financial relationships with AbbVie Inc., Johnson & Johnson, Advanced Neuromodulation Systems (Abbott), Alkermes, Alto Neuroscience, Boehringer-Ingelheim, Karuna Therapeutics, Inc., and Neumora.
- Mark Frye, MD. Reports financial relationships with Assurex Health, Baszucki Group, Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2), Mayo Foundation, Carnot Laboratories, American Physician Institute, and Chymia LLC.
- Nina Kraguljac, MD, FAPA.
- Rajesh Tampi, MD.
- Roger McIntyre, MD. Reports financial relationships with CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute, Sage, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, MindMed, Neurocrine, Neurawell, Supernus, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie and Atai Life Sciences, Bristol Myers Squib, Boehringer Ingelheim, Alkermes, Lundbeck, Janssen, Johnson & Johnson, and Neumora Therapeutics.
- Timothy Wilens, MD. Reports financial relatiionships with NIH (NIDA), Ironshore Pharmaceuticals, Elsevier Psychiatric Clinics of North America (ADHD), Guilford Press; Cambridge University Press, Gavin Foundation; Bay Cove Human Services, US National Football League (ERM Associates); US Minor/Major League Baseball, White Rhino/3D Therapeutics, Massachusetts General Hospital.
Planners
- Vishal Madaan, MD, APA Deputy Medical Director, Reports no financial relationships with commercial interests.
- Diana Clarke, PhD.
Accessibility for Participants with Disabilities
The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. Please contact the American Psychiatric Association at 202-559-3900, if you require assistance seven (7) business days prior to the start of a live webinar.
Technical Requirements
This internet-based CME activity is best experienced using any of the following:
- The latest and 2nd latest public versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer 11+
This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.
Optimal System Configuration:
- Browser: Google Chrome (latest and 2nd latest version), Safari (latest and 2nd latest version), Internet Explorer 11.0+, Firefox (latest and 2nd latest version), or Microsoft Edge (latest and 2nd latest version)
- Operating System: Windows versions 8.1+, Mac OS X 10.5 (Leopard) +, Android (latest and 2nd latest version), or iOS/iPad OS (latest and 2nd latest version)
- Internet Connection: 1 Mbps or higher
Minimum Requirements:
- Windows PC: Windows 8.1 or higher; 1 GB (for 32-bit)/2 GB (for 64-bit) or higher RAM; Microsoft DirectX 9 graphics device with WDDM driver; audio playback with speakers for programs with video content
- Macintosh: Mac OS X 10.5 or higher with latest updates installed; Intel, PowerPC G5, or PowerPC G4 (867MHz or faster) processor; 512 MB or higher RAM; audio playback with speakers for programs with video content